All In Biotech

Drug Trial Radar · NCT03824912

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis

Last checked: Nov 20, 2026Latest source record: Jun 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 831 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

831

Actual

Start

Aug 23, 2018

Primary completion

Jan 24, 2019

Study completion Jan 24, 2019

Sponsor

Lead sponsor
Encube Ethicals Pvt. Ltd.Industry
Sponsor type
Industry
Collaborators
Novum Pharmaceutical Research Services; ACM Global Laboratories
First posted
Jan 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

Conditions

  • Tinea Pedis

Interventions

  • Ketoconazole Cream 2%Drug

    Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.

  • Ketoconazole Cream 2% (G&W Laboratories Inc.)Drug

    Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.

  • PlaceboDrug

    Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population)Time frame: Two weeks after the end of treatment (Day 56 ± 4) (Equivalence)
  2. Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Superiority: Modified Intent-to-Treat Population)Time frame: Two weeks after the end of treatment (Day 56 ± 4) (Superiority)

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Long Beach Clinical Trial Services, Inc.

    Long Beach, California

  • International Dermatology Research, Inc.

    Miami, Florida

  • FXM Research Corp.

    Miami, Florida

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • FXM Research Miramar

    Miramar, Florida

  • MOORE Clinical Research, Inc.

    Tampa, Florida

  • PEAK Research, LLC

    Upper Saint Clair, Pennsylvania

  • FXM Research International

    Belize City, Belize

  • FXM Research International

    Castries, Saint Lucia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.